The Soviet Union invested heavily in peptide research during the Cold War, producing a distinct pharmacological tradition that continues today at the St. Petersburg Institute of Bioregulation and Gerontology and related laboratories. This work yielded Semax and Selank, two nootropic peptides still prescribed in Russia, and the Khavinson short peptides — Epithalon, Thymalin, Cortagen, Vesugen, and Pinealon — which are marketed online as anti-aging and regenerative compounds.
Western medicine has been slow to engage with this body of work. The reasons are not purely political. Language barriers, small study sizes, lack of randomization, and biological claims that strain plausibility have all contributed to a credibility gap. This article provides a fair assessment of what the Russian literature claims, where it falls short, and how to evaluate these compounds without either dismissal or uncritical acceptance.
Semax: Soviet origins and Western absence
Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in the 1980s at the Soviet Institute of Molecular Genetics. In Russia, it is approved as a nasal spray at concentrations of 0.1% and 1% for cognitive recovery after stroke and for certain optic nerve disorders. The proposed mechanism involves brain-derived neurotrophic factor (BDNF) upregulation and melanocortin receptor modulation.
Russian clinical studies, summarized in reviews by Gusev and colleagues, report improvements in attention, memory, and functional recovery in small patient cohorts. These studies are published primarily in Russian-language journals such as Zhurnal Nevrologii i Psikhiatrii, which are not indexed in PubMed. No Phase III randomized controlled trial of Semax has been published in an English-language, PubMed-indexed journal for any indication.
The pharmacokinetics of intranasal Semax are poorly characterized in Western literature. Nasal peptide absorption is highly variable and unpredictable, influenced by mucociliary clearance, enzymatic degradation, and individual nasal anatomy. Whether the doses used in Russian clinical practice achieve meaningful central nervous system concentrations is not established by independent Western studies.
Selank: anxiolytic claims without replication
Selank was developed alongside Semax and shares its Soviet origin. It is a heptapeptide with reported anxiolytic properties, marketed in Russia and some former Soviet states as a nasal spray. Russian clinical reports describe reduced anxiety in generalized anxiety disorder patients and improved stress adaptation.
The mechanism is attributed to modulation of GABA-A receptor subunit expression and inhibition of enkephalin-degrading enzymes. Like Semax, no Western regulatory agency has approved Selank. No English-language Phase III RCT exists. Claims that it is non-addictive and as effective as benzodiazepines are based on small Russian studies that have not been independently replicated.
A 2006 study by Umarova and colleagues, published in Zhurnal Nevrologii i Psikhiatrii, described anxiolytic effects in 60 patients with generalized anxiety disorder. The study lacked placebo control and blinding. Dropout rates and adverse events were not reported in detail. Without independent replication using modern trial methodology, these findings remain suggestive but not conclusive.
The Khavinson peptides: gene switches or speculation
Professor Vladimir Khavinson has spent decades developing what he calls tissue-specific short peptides. The framework posits that certain tripeptides and tetrapeptides act as gene switches, regulating expression of proteins specific to particular organs. It is an elegant theory. The evidence supporting it is thin.
Epithalon (Ala-Glu-Asp-Gly) is the most famous Khavinson peptide, promoted for telomerase activation and longevity. Khavinson's group reported increased telomere length and reduced mortality in elderly patients over a 12-year follow-up. These studies were small, non-randomized, and have not been replicated outside Russia. The concept of pharmacological telomerase activation for human longevity remains speculative.
Pinealon (Glu-Asp-Arg) is claimed to regulate gene expression in the central nervous system. Cortagen (Ala-Glu-Asp) is marketed for adrenal tissue, and Vesugen (Lys-Glu-Asp) for vascular health. The studies behind these claims are predominantly in vitro or in animal models. No Western laboratory has independently replicated the gene-switching effects, and the concept that a tripeptide administered nasally can predictably alter human gene expression is biologically implausible based on current molecular biology.
Why Western replication is lacking
Multiple factors explain the absence of Western replication. Language is the most immediate barrier. Many studies are published in Russian journals not indexed in PubMed or MEDLINE, making them invisible to Western systematic reviewers. Even when translated, the methodological descriptions often lack the detail required for modern CONSORT compliance.
Commercial incentives also play a role. Russian patents on these peptides do not translate into profit potential for Western pharmaceutical companies, which prefer compounds with clear intellectual property pathways and large market potential. The orphan-disease model does not apply here, and the anti-aging market, while large, is regulated as cosmetics rather than drugs in most jurisdictions.
Scientific caution is the final factor. Some Western reviewers have questioned whether short peptides administered by nasal spray can reach relevant tissue concentrations and produce the claimed genomic effects. The burden of proof lies with the claimant, and that burden has not been met by independent research.
Quality and sourcing: a minefield
Products labeled as Semax, Selank, or Epithalon from online vendors frequently fail third-party testing. Analytical studies of research chemical peptides have found significant rates of impurity, incorrect sequences, and endotoxin contamination. The problem is worse for Russian peptides because the supply chain often involves international shipping, customs delays, and temperature excursions that can degrade the product.
Nasal spray formulations add another layer of risk. Sterile manufacturing is difficult. Preservative stability is often unverified. A peptide nasal spray contaminated with bacteria or degraded by heat during transit is not just ineffective. It is potentially harmful.
How to evaluate claims about Russian peptides
When encountering claims about Russian peptides, apply these five criteria:
- Has the claim been replicated by an independent Western research group?
- Is the study published in a PubMed-indexed, peer-reviewed journal with full methodological transparency?
- Was the study randomized, placebo-controlled, and adequately powered?
- Is there a plausible mechanism supported by independent molecular biology data?
- Does the product have verified third-party testing including HPLC, mass spectrometry, and endotoxin analysis?
Evidence summary
Semax and Selank have the strongest Russian clinical data, but that data is geographically limited, methodologically weak, and unreplicated in the West. The Khavinson peptides rest on a theoretical framework that has not been validated by independent molecular biology research. None of these compounds are approved by the FDA, EMA, or any major Western regulatory agency.
For patients interested in Russian peptides, the honest assessment is that the risk-benefit ratio is unknown. The compounds may have pharmacological activity. They may not. Without independent, high-quality clinical trials, any recommendation for or against them rests on theory, tradition, or hope. None of these are substitutes for evidence. The regulatory status is equally clear: Semax and Selank are prescription drugs in Russia but unapproved research chemicals in the United States. Importing them for personal use violates FDA regulations and risks customs seizure. The legal and medical risks compound the scientific uncertainty. For now, Russian peptides belong in the same category as many other promising but unproven compounds: interesting enough to study, insufficient to recommend. Wait for the trials. The science will still be there when the data arrives. Until then, caution is the only rational position.